Teramo Advisors’s AbbVie ABBV Stock Holding History

Teramo Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,000	Closed	-$153K	–	22
2022 Q2	$153K	Buy	+1,000	New	+$153K	0.1%	15

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Teramo Advisors's ABBV Position: Q3 2022 in Review

Teramo Advisors sold out of AbbVie (ABBV) in Q3 2022, closing a stake of 1,000 shares — an estimated $153K sold.

Teramo Advisors first reported a position in ABBV in Q2 2022 and held it in 1 quarter. The position peaked at $153K in Q2 2022. 2,968 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.

Teramo Advisors reported no remaining AbbVie position as of Q3 2022 after selling out during the quarter.
Teramo Advisors sold 1,000 AbbVie shares in Q3 2022, an estimated $153K.
Teramo Advisors first reported a position in AbbVie in Q2 2022 and held it in 1 quarter.
Teramo Advisors's AbbVie position peaked at $153K in Q2 2022.
2,968 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.

Based on Teramo Advisors's 13F filing for Q3 2022, filed 27 Oct 2022.